Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CellSource Co., Ltd. ( (JP:4880) ) has provided an announcement.
CellSource Co., Ltd. announced a write-down of deferred tax assets and a discrepancy between its financial forecasts and actual results for the fiscal year ending October 31, 2025. The company reported lower net sales, operating profit, and ordinary profit than previously forecasted, primarily due to unmet order plans in its core businesses and an inability to fully offset decreased revenue despite managing expenses. The net income was significantly impacted by a deferred income tax expense from the write-down.
The most recent analyst rating on (JP:4880) stock is a Hold with a Yen547.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the medical industry, focusing on Contract Processing Services and Medical Device sales.
Average Trading Volume: 75,523
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen9.55B
Find detailed analytics on 4880 stock on TipRanks’ Stock Analysis page.